When complex multicellular organisms grow and develop, their tissues must undergo remodeling. As new cells begin to proliferate, old ...

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...

Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel ...

"This increased our interest in the epidermal growth factor receptor (EGFR) pathway because previous work indicated that it ...

“This increased our interest in the epidermal growth factor receptor (EGFR) pathway because previous work indicated that it ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

In a breakthrough study, researchers from the National University of Singapore (NUS) have developed a new way to deliver ...

Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...

AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application for accelerated approval in the US for datopotamab deruxtecan for the treatment of adult patients with locally ...

AstraZeneca and Daiichi Sankyo have submitted a new biologics license application (BLA) for accelerated approval for ...

The Guildford, England-based liquid biopsy company said the study undertaken by the National & Kapodistrian University of Athens used the Parsortix system to isolate and harvest circulating tumour ...

Dizal has submitted sunvozertinib’s new drug application (NDA) to the US Food and Drug Administration (FDA) aiming to secure approval for treating locally advanced or metastatic non-small cell lung ...